Introduction
Gentamicin is an aminoglycoside frequently used in the treatment of gram-negative infection. One of its main side effects is nephrotoxicity, even at the lower therapeutical doses. Gentamicin is specifically reabsorbed by proximal tubular cells, 2 and accumulated into the lysosomes, inducing PIP2-enriched phospholipidosis and thus, causes cellular necrosis. However, although gentamicin-induced nephrotoxicity is mainly tubular, and cellular necrosis confined to cells of the nephron segment where gentamicin is absorbed, chronic treatment with gentamicin has been reported to induce decreases in glomerular filtration rate (GFR). 4 Platelet activating factor (PAF) has been shown to be produced by the kidney 5'6 and to be involved in the reduction of GFR observed in experimental models of acute renal failure (ARF). 7'8 To assess whether PAF could be involved in the gentamicin-induced nephrotoxicity, we have studied in rats after gentamicin treatment, the effect on renal function and morphology of inhibiting the interaction of PAF with its receptor using a specific antagonist of PAF, BN- 
